Reprogramming of T Cells from Human Peripheral Blood

Loh, Yuin-Han; Hartung, Odelya; Hu, Li; Guo, Chunguang; Sahalie, Julie M.; Manos, Philip D.; Urbach, Achia; Heffner, Garrett C.; Grs̆ković, Marica; Vigneault, François; Lensch, M. William; Park, In Hyun; Agarwal, Suneet; Church, George M.; Collins, James J.; Irion, Stefan; Daley, George Q.

doi:10.1016/j.stem.2010.06.004

Cited by 285 publications

(222 citation statements)

References 23 publications

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…Because the AF cells we used in this study could be mixtures of different cell populations, we could not identify the origin of the iPS cells by cell type. Recently, it has been reported that blood cells may be a good source for generating iPS cells (37)(38)(39)(40)(41).…”

Section: Discussionmentioning

confidence: 99%

Generation of induced pluripotent stem cells using site-specific integration with phage integrase

Ye¹,

Chang²,

Lin³

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

To date, a large number of reports have described reprogramming many somatic cell types into induced pluripotent stem (iPS) cells, using different numbers of transcription factors and devising alternate methods of introducing the transcription factor genes or proteins into the somatic cells. Here, we describe a method using bacteriophage ΦC31 integrase to reprogram mouse embryonic fibroblasts and human amniotic fluid cells into iPS cells. These iPS cells showed morphology, surface antigens, gene expression, and epigenetic states similar to ES cells and formed teratomas with three germ layers in nonobese diabetic/severely compromised immunodeficient mice. Importantly, these iPS cells have only a single integration site in each cell line. The locations of integration favor the intergenic regions, and their distances from the adjacent genes extended from several hundred to >1 million bp. The effect of the insertion on the expression of these genes can be studied by RT-PCR. No insertion into microRNA gene loci was detected. Hence, it is possible to select cells in which adjacent gene functions are not affected, or the inserts can be removed if necessary. We conclude that phage integrase-mediated sitespecific recombination can produce iPS cells that have undisturbed endogenous gene function and could be safe for future human therapeutic application.

show abstract

Section: Discussionmentioning

confidence: 99%

Generation of induced pluripotent stem cells using site-specific integration with phage integrase

Ye¹,

Chang²,

Lin³

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Several groups have generated T cell-derived iPS cells, [5][6][7][8] but not much is known about differentiating these cells back into antigen-specific T cells.…”

Section: By Tracey Baas Senior Editormentioning

confidence: 99%

Rejuvenating T cells

Baas¹

2013

Science-Business eXchange

View full text Add to dashboard Cite

“…Blood sample collection and storage are among the routine procedures in hospitals and clinics. Therefore, significant efforts have been made to develop efficient and safe procedures for reprogramming various types of blood cells (Table 1) [10,11,[13][14][15][16][17][18][19][20][21]. Umbilical cord blood (UCB) cell banks provide another rich source for cells with diverse HLA types.…”

Section: Generation Of Patient-specific Ipscsmentioning

confidence: 99%

“…T cells, which are abundant in peripheral blood and amenable to ex vivo expansion after stimulation of T cell receptor (TCR) activation, were the first subtypes of lineage-committed human blood cells being reprogrammed [16][17][18]. Analyses of the TCR genomic loci had shown the evidence of V(D)J recombination in resultant iPSCs, demonstrating their T cell origin [16][17][18]24]. These studies also provided the most convincing evidence that terminally differentiated human cells can be reprogrammed into a pluripotent state.…”

Section: Generation Of Patient-specific Ipscsmentioning

confidence: 99%

Promise and challenges of human iPSC-based hematologic disease modeling and treatment

Chou

Cheng

2012

Int J Hematol

View full text Add to dashboard Cite

Postnatal hematopoietic stem cells (HSCs) from umbilical cord blood and adult marrow/blood have been successfully used for treating various human diseases in the past several decades. However, the availability of optimal numbers of HSCs from autologous patients or allogeneic donors with adequate match remains a great barrier to improve and extend HSC and marrow transplantation to more needing patients. In addition, the inability to expand functional human HSCs to sufficient quantity in the laboratory has hindered our research and understanding of human HSCs and hematopoiesis. Recent development in reprogramming technology has provided patient-specific pluripotent stem cells (iPSCs) as a powerful enabling tool for modeling disease and developing therapeutics. Studies have demonstrated the potential of human iPSCs, which can be expanded exponentially and amenable for genome engineering, for using in modeling both inherited and acquired blood diseases. Proof-of-principle studies have also shown the feasibility of iPSCs in gene and cell therapy. Here, we review the recent development in iPSC-based blood disease modeling, and discuss the unsolved issues and challenges in this new and promising field.

show abstract

Reprogramming of T Cells from Human Peripheral Blood

Cited by 285 publications

References 23 publications

Generation of induced pluripotent stem cells using site-specific integration with phage integrase

Generation of induced pluripotent stem cells using site-specific integration with phage integrase

Rejuvenating T cells

Promise and challenges of human iPSC-based hematologic disease modeling and treatment

Contact Info

Product

Resources

About